TR200101256T2 - DNA ile aşılamada geliştirmeler - Google Patents

DNA ile aşılamada geliştirmeler

Info

Publication number
TR200101256T2
TR200101256T2 TR2001/01256T TR200101256T TR200101256T2 TR 200101256 T2 TR200101256 T2 TR 200101256T2 TR 2001/01256 T TR2001/01256 T TR 2001/01256T TR 200101256 T TR200101256 T TR 200101256T TR 200101256 T2 TR200101256 T2 TR 200101256T2
Authority
TR
Turkey
Prior art keywords
enhancements
mammal
compound
disease state
antigenic peptide
Prior art date
Application number
TR2001/01256T
Other languages
English (en)
Inventor
Charo Jehad
Kiessling Rolf
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200101256T2 publication Critical patent/TR200101256T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bir memeliyi bir hastalik durumuna karsi asilamak için bir yöntem olup, bu yöntem sözü edilen memeliye, uygun bir vektör içinde, hastalik durumu ile iliskili bir antijenik peptid kodlayan bir nükleotid dizisi verilmesini; buna ilaveten sözü edilen memeliye, antijenik peptid tarafindan baslatilan hem hümoral hem de hücresel bagisiklik tepkilerini artiran bir bilesik verilmesini içerir; bu bilesik, burada verilen bir listeden seçilir ve bu bilesik tercihan Tucaresol veya uygun durumlarda, bunun fizyolojik açidan kabul edilebilir bir tuzu veya esteridir.
TR2001/01256T 1998-08-26 1999-08-25 DNA ile aşılamada geliştirmeler TR200101256T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9818627.3A GB9818627D0 (en) 1998-08-26 1998-08-26 Improvements in dva vaccination

Publications (1)

Publication Number Publication Date
TR200101256T2 true TR200101256T2 (tr) 2001-10-22

Family

ID=10837881

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01256T TR200101256T2 (tr) 1998-08-26 1999-08-25 DNA ile aşılamada geliştirmeler

Country Status (22)

Country Link
US (1) US7074770B1 (tr)
EP (1) EP1107785B1 (tr)
JP (1) JP2002523469A (tr)
KR (1) KR20010072983A (tr)
CN (1) CN1326358A (tr)
AT (1) ATE411043T1 (tr)
AU (1) AU747643B2 (tr)
BR (1) BR9913323A (tr)
CA (1) CA2341544A1 (tr)
CZ (1) CZ2001717A3 (tr)
DE (1) DE69939747D1 (tr)
ES (1) ES2313791T3 (tr)
GB (1) GB9818627D0 (tr)
HU (1) HUP0103214A3 (tr)
IL (1) IL141623A0 (tr)
NO (1) NO20010922L (tr)
NZ (1) NZ510206A (tr)
OA (1) OA11644A (tr)
PL (1) PL346299A1 (tr)
TR (1) TR200101256T2 (tr)
WO (1) WO2000012121A1 (tr)
ZA (1) ZA200101539B (tr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
DK1913957T3 (da) * 1999-11-03 2010-05-10 Powderject Vaccines Inc Genetiske adjuvant-vacciner
ES2340617T3 (es) * 1999-11-03 2010-06-07 Powderject Vaccines, Inc. Vacunas geneticas con adyuvantes.
WO2001076626A2 (en) * 2000-04-11 2001-10-18 Galenica Pharmaceuticals, Inc. Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
WO2005000778A1 (ja) * 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
CN100415876C (zh) * 2003-09-05 2008-09-03 杭州浙大康泰生物技术有限公司 艾滋病重组腺病毒疫苗
WO2011073796A2 (en) 2009-12-16 2011-06-23 Chrontech Pharma Ab Injection needle and device
WO2012172424A1 (en) 2011-06-15 2012-12-20 Crontech Pharma Ab Injection needle and device
CN104135859B (zh) * 2011-12-28 2017-06-27 全球血液疗法公司 取代的苯甲醛化合物及其用于增加组织氧合的方法
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
JP6463327B2 (ja) 2013-03-15 2019-01-30 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
DK3102208T4 (da) 2014-02-07 2024-08-26 Global Blood Therapeutics Inc Krystallinsk polymorph af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
CA2940961C (en) 2014-02-26 2022-07-12 Elma FRIAS Nitrobenzaldehyde proton release for manipulation of cellular acidosis
EP3265090A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating cancer associated with a ras mutation
US11267807B2 (en) * 2015-10-28 2022-03-08 The Brigham And Women's Hospital, Inc. Use of small molecule inhibitors to KLF10 for modulation of T regulatory cells and cancer immunotherapy
EP3383392A1 (en) 2015-12-04 2018-10-10 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MY192703A (en) 2016-02-08 2022-09-02 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN109232238B (zh) * 2018-08-29 2022-05-17 北京勤邦生物技术有限公司 吉非罗齐半抗原、人工抗原和抗体及其制备方法和用途
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
CA3190768A1 (en) * 2020-08-26 2022-03-03 Mathias Frederic FRANCOIS Antiviral sox inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
DK0609606T3 (tr) 1992-10-01 1997-03-17 Wellcome Found
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
EP1170368B1 (en) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit

Also Published As

Publication number Publication date
GB9818627D0 (en) 1998-10-21
PL346299A1 (en) 2002-01-28
US7074770B1 (en) 2006-07-11
BR9913323A (pt) 2001-12-04
OA11644A (en) 2004-11-22
CZ2001717A3 (cs) 2001-10-17
WO2000012121A1 (en) 2000-03-09
KR20010072983A (ko) 2001-07-31
IL141623A0 (en) 2002-03-10
AU747643B2 (en) 2002-05-16
ZA200101539B (en) 2002-02-25
EP1107785B1 (en) 2008-10-15
CN1326358A (zh) 2001-12-12
EP1107785A1 (en) 2001-06-20
NZ510206A (en) 2003-08-29
DE69939747D1 (de) 2008-11-27
CA2341544A1 (en) 2000-03-09
ATE411043T1 (de) 2008-10-15
AU5740299A (en) 2000-03-21
NO20010922L (no) 2001-04-23
NO20010922D0 (no) 2001-02-23
JP2002523469A (ja) 2002-07-30
HUP0103214A3 (en) 2003-10-28
HUP0103214A2 (hu) 2001-12-28
ES2313791T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NZ514887A (en) IBD-associated microbial antigens and methods of using same
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
IS5329A (is) Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
PT900380E (pt) Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados
HK1039749A1 (en) Use of expressions of ctl and t-helper lymph cellsin vaccination
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
BR9712971A (pt) Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica
BR9913446A (pt) Produtos de aglicona e métodos de uso
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
EP1242049A4 (en) HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINES
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
AU8727201A (en) Genes involved in intestinal inflammatory diseases and use thereof
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
HK1048819A1 (en) Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
MXPA03010261A (es) Metodos para tratar cancer.
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
GB9914045D0 (en) Novel compounds
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
WO2000073432A3 (en) Activation of dendritic cells to enhance immunity